Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: Forest Laboratories
• Treatments: Memantine

Criteria

Inclusion Criteria::

• Meets DSM-IV criteria for Major Depressive Disorder

• 18 to 75 years of age and able to provide legal consent

• Referred to Stanford ECT service by treating physician for unilateral electroconvulsive therapy with inpatient hospitalization

• Competed process for consenting to the clinical use of ECT according to California State law

• Females of childbearing potential will be required to use a double-barrier method of contraception, which includes foam and either condom and diaphragm, IUD, and/or implant during study. Exclusion Criteria:- Treatment with ECT in the 6 months prior to screening

• Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening

• Use of alcohol or illegal drugs within seven days of randomization or during study. Patients may be excluded for use during a period greater than 7 days, per study physician's discretion

• Presence of unstable or untreated cardiovascular disease, hypertension, or endocrine disorder as determined by the investigator

• use of antipsychotic, antidepressant, or other prescription medications unless dose is stable for at least 7 days prior to randomization.

• Use of any investigational treatment within 30 days of randomization

• Previous allergic reaction to memantine or drugs of similar chemical structure.

• Women who are pregnant or breastfeeding are not advised to participate in the research study

• Any neurological disorder or organic brain condition that would confound neurocognitive testing